2 March 2023 - The Government has confirmed plans to raise the revenue clawback rate paid by pharmaceutical firms subject to the Statutory Scheme for branded medicines from 24.4% to 27.5%

In February, the Association of the British Pharmaceutical Industry warned that the proposed rate rise would send the worst possible signal to global investors and boardrooms at a time UK life sciences are already facing significant challenges.

Read ABPI press release